


Pfizer ApS

Annual Report 2016/17

Chairman of the Annual General Meeting

26/04/2018



NICHOLAS WILLIAM ROE STENDERUP

Lautrupvang 8, 2750 Ballerup

Registration no: 66 35 19 12

The Annual Report contains 27 pages

Contents

Statement by the Board of Directors and the Executive Board	2
Independent auditors' report	3
Management's review	6
Income statement	12
Balance sheet	13
Statement of Changes in Equity	15
Notes	16

Statement by the Board of Directors and the Executive Board

The Board of Directors and the Executive Board have today discussed and approved the annual report of Pfizer ApS for the financial year 1 December 2016 – 30 November 2017.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

It is our opinion that the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 30 November 2017 and of the results of the Company's operations for the financial year 1 December 2016 – 30 November 2017.

In our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's its financial position.


We recommend that the annual report be approved at the annual general meeting.

Ballerup, 24 April 2018

Executive Board:


Henriette Dræbye Rosenquist

Board of Directors:


Nanna Jannov
Chairman


Kamila K. Kozikowska


Lars Møller


Anne Birgitte Hein


Henriette Rosenquist


Stefano Podesta

Independent auditor's report

To the shareholders of Pfizer ApS

Opinion

We have audited the financial statements of Pfizer ApS for the financial year 1 December 2016 – 30 November 2017 comprising income statement, balance sheet, statement of changes in equity and notes. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 30 November 2017 and of the results of the Company's operations for the financial year 1 December 2016 – 30 November 2017 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibility for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control that Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Independent auditor's report

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements in Denmark will always detect a material misstatement when it exists. Misstatements may arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of financial statement users made on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also

- identify and assess the risks of material misstatement of the company financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.

- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.

- conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the under-lying transactions and events in a manner that gives a true and fair view.

Independent auditor's report

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 24 April 2018
KPMG
Statsautoriseret Revisionspartnerselskab
CVR no. 25 57 81 98



Lau Bent Baun
State Authorised Public Accountant
mne 26708



Joakim Juul Larsen
State Authorised Public Accountant
mne 32803

Management's review

Company details

Telephone: +45 44 20 11 00
Telefax: +45 44 20 11 01
Web site: www.pfizer.dk
Registration No. 66 35 19 12
Registered office: Lautrupvang 8, 2750 Ballerup, Denmark

Board of Directors

Nanna Jannov
Kamila K. Kozikowska
Lars Møller
Anne Birgitte Hein
Henriette Rosenquist
Stefano Podesta

Executive Board

Henriette Rosenquist

Auditors

KPMG
Statsautoriseret Revisionspartnerselskab
Dampfærgevej 28
DK-2100 Copenhagen

Financial highlights

DKK'000	2016/17	2015/16	2014/15	2013/14	2012/13
Key figures					
Revenue	387,024	426,823	528,869	509,882	521,407
Operating profit	23,032	18,760	39,955	6,870	23,921
Net loss from interest income and expense and similar items	35	6	158	-366	-1,942
Profit for the year	17,982	11,789	27,705	5,644	22,425
Financial ratios					
Fixed assets	3,355	27,897	2,697	3,360	3,668
Current assets	528,579	488,117	571,676	536,448	498,676
Total assets	531,934	516,015	574,373	539,808	502,344
Capital and reserves	402,342	384,360	372,571	344,869	339,246
Provisions	10,061	5,567	4,287	11,141	7,354
Short-term liabilities other than provisions	119,531	126,088	197,515	183,800	155,745
Investment in tangible fixed assets	-	-	-	218	136
Financial ratios					
Operating profit ratio	6.0	4.4	7.6	1.3	4.6
Return on investment	6.0	5.1	11.3	2.1	7.5
Current ratio	442.2	387.1	289.4	291.9	320.2
Equity ratio	75.6	74.5	64.9	63.9	67.5
Return on equity	4.7	3.2	7.9	1.7	6.8
Average number of employees					
Average number of employees	145	131	138	143	118

* Financial highlights for the period 2012/2013 have been restated with the transferring of GEP activities, assets and liabilities from Pfizer Aps to Pfizer PFE Aps on 1 December 2013.

The financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios "Recommendations and Financial Ratios 2015".

Financial highlights

The financial ratios stated in the survey of financial highlights have been calculated as follows:

Operating profit ratio

$$\frac{\text{Operating profit} \times 100}{\text{Revenue}}$$

Return on investment

$$\frac{\text{Operating profit} \times 100}{\text{Average invested capital}}$$

Current ratio

$$\frac{\text{Current assets} \times 100}{\text{Short-term liabilities}}$$

Equity ratio

$$\frac{\text{Equity at year end} \times 100}{\text{Total equity and liabilities at year end}}$$

Return on equity

$$\frac{\text{Profit for the year} \times 100}{\text{Average equity}}$$

Financial statements 1 December - 30 November

Management's review

Operating Review

Activities

Pfizer ApS is part of the American Pfizer Group, a multinational pharmaceutical group listed on the New York Stock Exchange.

Pfizer ApS is a fully owned subsidiary of Pfizer Inc. and its activities primarily consist of marketing, distribution and sale of the Pfizer Group's pharmaceutical and consumer products and, to a limited extent, the coordination of clinical studies performed by other parties in Denmark for the Pfizer Group's products. Pfizer ApS markets, distributes and sells pharmaceutical goods in Denmark, as well as to a third party distributor in Iceland.

Corporate Social Responsibility

Pfizer ApS considers corporate social responsibility a factor of increasing importance for the business. The Company has not worked out independent strategies and policies on the subject. In accordance with the § 99a of the Danish Financial Statement act however, the Company's ultimate parent company Pfizer Inc. has strategies and policies regarding corporate social responsibility for the Group, including impacts on climate, environment and human rights which Pfizer ApS continuously works with.

More information about Corporate Social Responsibility is described in Pfizer's website at: http://www.pfizer.com/investors/financial_reports/financial_reports

The development of the year

Turnover in Pfizer ApS decreased in 2016/17 from DKK 427 million to DKK 387 million. The great majority of this decline is driven by Enbrel, a major brand with loss of exclusivity in 2015, facing biosimilar competition in 2016 and with a significant revenue decline taking place from mid-2016. In addition, Haemophilia brands declined vs. prior year due to competitive pressure. This decline is partly offset by growth in several Oncology brands, the newly launched Ibrance being the largest with additional DKK 47 million vs. last year.

The increased price pressures in Denmark continue leading to increasing levels of parallel trade affecting several retail brands and, in certain cases also some hospital brands.

Financial statements 1 December - 30 November

Management's review

Operating Review

The operating profit increased in 2016/17 from DKK 19 million to DKK 23 million. The result for the year is satisfactory, with a turnover and operating profit within the range of expectations set for 2016/17.

Marketing and Distribution costs increased by DKK 3.5 million compared to prior year due to additional investment in the brand Eliquis as well as, field force investment in Iceland. In addition, the Vaccines & Oncology business units continued increasing their investment vs. prior years to support new product launches.

Development expenses increased by DKK 14.4 million compared to prior year due to higher investments in the Consumer division including higher facility management costs for the Consumer R&D site taking place during 2017 before the decision to close the Consumer R&D site was made at year-end 2017, increased investment in the Oncology and the Vaccines business units as well as, higher regulatory fees due to the integration of the Hospira business.

The increase of 21 million DKK in administrative expenses is mostly explained by the R&D equipment write-off net of expected sales proceeds for the portion to be sold and, other restructuring and exit costs related to the closure of the Consumer R&D site based in Søborg. All costs associated to the closure of the R&D Søborg site were recharged to Ferrosan A/S.

Financial position

The Company's share capital and reserves amounted to DKK 402 million at year end 2016/17, which is 76% of the balance sheet total.

Research and development activities

Research and development activities within the Pharmaceutical division of Pfizer ApS comprise clinical trials, regulatory affairs, drug safety and medical affairs. The Pharmaceutical division of Pfizer ApS only performs research and development on behalf of other group enterprises.

Research and development for the Consumer division comprise product development including product design, nutritional science (medical affairs/clinical trials), project management and regulatory affairs.

Pfizer ApS does not acquire ownership to intellectual rights neither for the Pharmaceutical nor for the Consumer division.

Financial statements 1 December - 30 November

Management's review

Knowledge resources

It is the goal of Pfizer to attract the best people, enabling Pfizer to constantly develop and adapt the Company to an ever-changing world. Through training Pfizer constantly seeks to develop the employees, in terms of knowledge of the products, as well as developing competencies and training in core values.

Operating Review

Outlook

For 2017/18 the Company expects revenue to increase. This will be largely driven by the Oncology and Vaccines Business Units. Operating profit is expected at a similar level or slightly above 2016/2017.

The prescription activity is expected to grow due to increased productivity in the secondary care and market growth as a result of ageing population. The industry as a whole in Denmark is exposed to competition from parallel importers, biosimilar entries and generic substitution. At the same time, public health costs are under supervision, a good example is the recently created Medicines Council.

Events after the balance sheet date

No material events have occurred subsequent to 30 November 2017 which significantly affects the assessment of the annual report.

Target figures regarding the under-represented gender in the Board of Directors

In accordance with section §99 b of the Danish Financial Statements Act, we have adopted a culture of diversity and inclusion. There is no disparity between the genders both at the Board and managerial levels. Our Board of Directors consists of 6 members, of which 4 females and 2 males. As this ratio is considered balanced in regards to 99b, no target has been set to increase the gender underrepresentation. In respect to other management levels, no gender is under represented with less than 40% for FY17, thus no specific policy has been adopted.

Financial statements 1 December - 30 November

Income statement

DKK'000	Note	2016/17	2015/16
Revenue	2	387,024	426,823
Cost of sales		-256,198	-287,944
Gross margin		130,826	138,879
Marketing and distribution costs	3	-109,028	-105,555
Development expenses	3	-88,579	-74,146
Administrative expenses	3,4,5	-82,493	-61,802
		-149,274	-102,624
Other operating income/expenses, net	6	172,306	121,384
Operating profit		23,032	18,760
Net interest income and expenses and similar items	7	35	6
Profit before tax		23,067	18,766
Tax on profit for the year	8	-5,085	-6,977
Profit for the year		17,982	11,789

Note 1 – Accounting Policies

Note 9 – Proposed Profit Allocation

Financial statements 1 December - 30 November

Balance sheet as at 30 November

DKK'000	Note	2017	2016
ASSETS			
Non-current assets	10		
Fixtures and fittings, tools and equipment		3,355	21,336
Property, plant and equipment under construction		-	6,561
Total non-current assets		3,355	27,897
Current assets			
Inventories		131,964	86,311
Receivables			
Trade receivables		45,834	44,184
Amounts owed by group enterprises		338,297	347,126
Other receivables		3,010	195
Corporation tax	11	-	3,400
Prepayments	12	1,371	1,368
Deferred tax	13	7,414	4,871
		395,926	401,144
Cash and bank balances		688	663
Total current assets		528,579	488,117
TOTAL ASSETS		531,934	516,015

Financial statements 1 December - 30 November

Balance sheet as at 30 November

DKK'000	Note	2017	2016
EQUITY AND LIABILITIES			
Equity	14		
Share capital		250,771	250,771
Retained earnings		151,571	133,589
Total equity		402,342	384,360
Provisions			
Other provisions	15	10,061	5,567
Total provisions		10,061	5,567
Short-term liabilities other than provisions			
Trade payables		24,804	34,877
Amounts owed to group enterprises		39,341	40,503
Other payables	16	55,386	50,708
Total liabilities		119,531	126,088
TOTAL EQUITY AND LIABILITIES		531,934	516,015

Note 17 – Contingent liabilities and other financial obligations

Note 18 – Related Parties

Financial statements 1 December - 30 November

Statement of changes in equity

DKK'000	Share Capital	Retained Earnings	Total
Equity at 1 December 2016	250,771	133,589	384,360
Transferred from profit for the year	-	17,982	17,982
Equity at 30 November 2017	250,771	151,571	402,342

Financial statements 1 December - 30 November

Notes

1 Accounting Policies

The annual report for 2016/2017 has been prepared in accordance with the provisions applying to class C (large) enterprises under the Danish Financial Statements Act.

As from 1 December 2016, the Company has implemented Act no. 738 of 1 June 2015. This has entailed the following changes to recognition and measurement:

— Going forward, the residual value of property, plant and equipment must be reassessed on an ongoing basis. Pursuant to the transition provisions of the Act, any adjustments to residual values must be made prospectively as an accounting estimate without restatement of comparative figures and without effect on equity.

The changes have no monetary effect on the income statement or the balance sheet for 2016/17 or for the comparative figures.

Apart from the above, the accounting policies used in the preparation of the financial statements are consistent with those of last year.

Foreign currency translation

Transactions in foreign currencies are translated at the exchange rates at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and at the date of payment are recognised in the income statement as interest income or expense and similar items.

Receivables and payables and other monetary items denominated in foreign currencies that have not been settled at the balance sheet date are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and at the date at which the receivable or payable arose or was recognised in the latest financial statements is recognised in the income statement as interest income or expense and similar items.

Income statement

Revenue

Revenue from the sale of goods for resale is recognized in the income statement provided that delivery and transfer of risk to the buyer has taken place before year end and that the income can be reliably measured and is expected to be received. Revenue is measured exclusive of VAT and taxes related to sale.

Financial statements 1 December - 30 November

Segment information

Information is provided on business segments. Segment information is based on the Company's accounting policies, risks and internal financial management.

Cost of sales

Cost of sales comprises the cost of goods and services sold during the year.

Marketing and distribution costs

Costs incurred in marketing and distributing goods sold during the year and in conducting sales campaigns etc. during the year are recognised as marketing and distribution costs. Also, costs relating to sales staff, advertising, exhibitions and depreciation are recognised as marketing and distribution costs.

Development expenses

Development expenses of the Pharmaceutical division comprise costs related to clinical trials, regulatory affairs, drug safety and medical affairs. The Pharmaceutical division of Pfizer ApS only performs research and development on behalf of other group enterprises.

Development expenses of the Consumer division comprise product development including product design, nutritional science (medical affairs/clinical trials), project management and regulatory affairs.

Administrative expenses

Administrative expenses comprise expenses incurred during the year for management and administration, including expenses for administrative staff, office premises and office expenses, and depreciation.

Other operating income and expenses

Other operating income and expenses comprise items secondary to the principal activities of the enterprise. Other operating income mainly includes income from research and development, marketing and administrative services provided to other Pfizer entities.

Interest income and expense and similar items

Interest income and expense and similar items comprise interest income and expense, gains and losses on payables and transactions denominated in foreign currencies as well as surcharges and refunds under the on-account tax scheme etc.

Financial statements 1 December - 30 November

Tax on profit for the year

Tax for the year comprises current tax and changes in deferred tax for the year. The tax expense relating to the profit/loss for the year is recognised in the income statement, and the tax expense relating to changes directly recognised in equity is recognised directly in equity.

Balance sheet

Property, plant and equipment

Property, plant and equipment are measured at cost less accumulated depreciation and impairment loss. Cost comprises the purchase price and any costs directly attributable to the acquisition until the date when the asset is available for use.

Depreciation is provided on a straight-line basis over the expected useful life of the assets. The expected useful life is as follows:

Leasehold improvements, fixtures and fittings, tools and equipment	8-12 years
--------------------------------------------------------------------	------------

The useful life and residual value are reassessed annually. Changes are treated as accounting estimates, and the effect on depreciation is recognised prospectively.

Fixed assets under construction are recognised and measured at cost at the balance sheet date. Upon entry into service, the cost is transferred to the relevant group of property, plant and equipment

Depreciation is recognised in the income statement as marketing and distribution costs, development costs and administrative expenses, respectively.

Impairment

The carrying amount of property, plant and equipment is subject to an annual impairment test besides depreciation.

When there is an indication that assets may be impaired, an impairment test is made of each asset or group of assets, respectively. Impairment is made to the lower of recoverable amount of the asset and the carrying amount.

Inventories

Inventories are measured at cost in accordance with the FIFO method. Where the net realisable value is lower than cost, inventories are written down to this lower value.

The net realisable value of inventories is calculated as the sales amount less costs of completion and costs necessary to make the sale and is determined taking into account marketability, obsolescence and development in expected sales price.

Receivables

Receivables are measured at amortised cost. Provisions are made for anticipated losses.

Financial statements 1 December - 30 November

Prepayments

Prepayments comprise costs incurred concerning subsequent financial years.

Capital and reserves - dividends

Proposed dividends are recognised as a liability at the date when they are adopted at the annual general meeting (declaration date). The expected dividend payment for the year is disclosed as a separate item under capital and reserves.

Corporation tax and deferred tax

Current tax payable and receivable is recognised in the balance sheet as tax computed on the taxable income for the year, adjusted for tax on the taxable income of prior years and for tax paid on account.

Deferred tax is measured using the balance sheet liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items where temporary differences, apart from business combinations, arise at the date of acquisition without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on the planned use of the asset or settlement of the liability, respectively.

Deferred tax assets, including the tax base of tax loss carry forwards, are recognised under investments at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity and jurisdiction.

Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax.

The Company is jointly taxed with all Danish group entities in the Pfizer Group. The current Danish corporate tax is allocated among the jointly taxed Danish companies in proportion to their taxable income (full allocation with reimbursement for tax losses).

Other provisions

Provisions comprise anticipated costs relating to returned goods and restructuring provisions. Provisions for returns are measured and recognised based on Management's experiences of returned goods.

Financial statements 1 December - 30 November

Financial liabilities

Financial liabilities, comprising trade payables and amounts owed to group enterprises are measured at amortised cost. Other liabilities are measured at net realisable value.

Cash flow statement

Pfizer ApS has not prepared a cash flow statement because the Company is included in the consolidated cash flow statement for the ultimate parent company Pfizer Inc. which can be found in the “for Investors” section under *2017 Financial Report* at www.pfizer.com

Financial statements 1 December - 30 November

2 Segment information

Geographical breakdown

DKK'000	Denmark Pharma- ceutical Products	Denmark Consumer Products	Iceland	Total
2016/17				
Revenue	319,444	37,893	29,687	387,024
2015/16				
Revenue	358,626	38,889	29,308	426,823

All revenue is related to the sale of prescription medicine and consumer health.

DKK'000	<u>2016/17</u>	<u>2015/16</u>
3 Staff costs		
Wages and salaries	124,550	118,324
Pensions	11,035	9,846
Other social security costs	732	640
Re-invoiced	-	150
	<u>136,317</u>	<u>128,960</u>

Staff costs are recognised as follows in the financial statements:

Marketing and distribution costs	55,644	50,319
Development expenses	48,351	45,562
Administrative expenses	32,322	33,079
	<u>136,317</u>	<u>128,960</u>
Average number of employees	<u>145</u>	<u>131</u>

Pursuant to Section 98b of the Danish Financial Statements Act, remuneration to Management is not disclosed. No emoluments have been paid to the Board of Directors.

Financial statements 1 December - 30 November

DKK'000	2016/17	2015/16
4 Depreciation and impairment loss		
Property, plant and equipment		
Depreciation for the year	3,645	2,148
	<u>3,645</u>	<u>2,148</u>

Depreciation and impairment losses are recognised as follows in the financial statements :

Development Expenses	1,230	54
Administrative expenses	2,415	2,094
	<u>3,645</u>	<u>2,148</u>

5 Fees paid to auditors appointed at the annual general meeting

Statutory audit	581	480
	<u>581</u>	<u>480</u>

Statutory audit fees include DKK 68,628 for Ferrosan A/S and Ferrosan International A/S audits, these costs were recharged to the Ferrosan group affiliates.

6 Other operating income, net

Sales & Marketing service	20,401	16,384
Administrative services	95,190	56,902
Development services	56,715	48,098
	<u>172,306</u>	<u>121,384</u>

Financial statements 1 December - 30 November

DKK'000	2016/17	2015/16
7 Net interest income and expenses and similar items		
Interest income, DKK nil (2015/16: DKK 10 thousand) of which is intra-group	-	10
Foreign exchange adjustments	163	175
Interest expenses, DKK 73 thousand (2015/16: DKK 19 thousand) of which is intra-group	-73	-19
Bank charges	-55	-55
Other Expenses	-	-105
	<u>35</u>	<u>6</u>
8 Tax on the profit for the year		
Corporation tax on profit for the year	7,516	6,844
Adjustment for deferred tax	-2,544	18
Adjustments to taxes from prior years	113	115
	<u>5,085</u>	<u>6,977</u>
9 Proposed Profit Allocation		
Allocation to retained earnings	17,982	11,789
	<u>17,982</u>	<u>11,789</u>

Financial statements 1 December - 30 November

DKK'000

10 Property, Plant and equipment

	Fixtures and fittings, tools and equipment	Under construction	Total
Costs at 30 November 2016	35,815	6,561	42,376
Opening Adjustment	-	-1,024	-1,024
Additions	1,964	998	2,962
Retirement	-114	-	-114
Reclassification	6,535	-6,535	-
Write-Off	-33,327	-	-33,327
Costs at 30 November 2017	10,873	-	10,873
Depreciation at 30 November 2016	-14,479	-	-14,479
Depreciation	-3,645	-	-3,645
Disposals	114	-	114
Write-Off	10,492	-	10,492
Depreciation at 30 November 2017	-7,518	-	-7,518
Carrying amount at 30 November 2017	3,355	-	3,355

	2016/17	2015/16
11 Corporation tax		
Tax on taxable income for the year	-7,516	-6,844
Joint taxation loss relief	7,516	6,844
Refunds outstanding from prior years	-	3,400
Receivable / (Payable) corporation tax at 30 November	-	3,400

12 Prepayments		
Other prepayments	1,371	1,368
	1,371	1,368

Financial statements 1 December - 30 November

DKK'000	2016/17	2015/16
13 Deferred tax		
Deferred tax 1 December	4,871	4,889
Adjustment for deferred tax from prior years	1,448	-227
Adjustment of deferred tax	1,095	209
Deferred tax 30 November	7,414	4,871

Deferred tax relates to plant and equipment, inventories, receivables, other provisions and other payables. The deferred tax asset is expected to be realisable within the foreseeable future.

14 Capital and reserves

The share capital comprises 250,771 thousand issued shares with a nominal value of 1 DKK each.

The changes in share capital for the last 5 years can be specified as follows:

	2016/17	2015/16	2014/15	2013/2014	2012/13
Share Capital at 1 December	250,771	250,771	250,771	250,771	250,771
Share capital at 30 November	250,771	250,771	250,771	250,771	250,771

15 Other provisions

Provision for returned goods

Provision for returned goods 1 December	367	875
Used during the year	-1,364	-2,943
Provision for the year	1,842	2,435
Provision for returned goods 30 November	846	367

The provisions comprise of anticipated costs relating to returned goods. The Company expects to use the provision over the next year.

Financial statements 1 December - 30 November

DKK'000	2016/17	2015/16
Provision for Restructuring		
Provision for Restructuring 1 December	5,200	3,412
Used during the year	-11,654	-3,797
Provision for the year	15,669	5,585
Provision for Restructuring 30 November	9,215	5,200

The majority of the accrued restructuring initiatives will be utilized by the end of the year 2017, except for DKK 836 thousand that will be used in 2018.

Total Provisions 30 November	10,061	5,567
-------------------------------------	---------------	--------------

16 Other payables

VAT and taxes	10,599	2,591
Payable wages and salaries inclusive of holiday provision	30,425	32,061
Other payables	14,362	16,056
	55,386	50,708

Payable wages and salaries include amounts for employees dismissed at 30 November 2017.

17 Contingent liabilities and other financial obligations

Lease obligations

The Company has entered into operating leases regarding cars and other operating equipment. The remaining payments for lease obligations amount to DKK 6,2 million (2015/16 DKK 9,2 million).

On December 14 2012, the Company entered into a commercial lease agreement with Wihlborgs A/S to rent 39.11% of the total gross surface area (4,544 of 11,620 m²) of the building located in Lautrupvang 8, Ballerup, previously owned by the Company.

The cost of the annual rent excluding VAT is DKK 3,3 million. This amount is payable in four quarterly installments due 1st January, 1st April, 1st June and 1st October. Both parties may terminate the lease including roof terrace area and parking places by giving six months' prior written notice to expire on the last day of a month. The Company may terminate the lease including roof terrace area and parking places to expire no earlier than 1st September 2020. The landlord may terminate the lease including roof terrace area and parking places – except in the event of breach – to expire no earlier than 1st September 2032.

Joint liability Pfizer ApS and Pfizer PFE ApS

On 1 December 2013 the GEP activities of Pfizer ApS were transferred to Pfizer PFE ApS in a demerger. Pfizer ApS and Pfizer PFE ApS are joint and several liable for liabilities that

Financial statements 1 December - 30 November

consisted at the date the demerger plan was published. However the joint and several liability cannot exceed the net assets transferred to each company in the demerger which for Pfizer ApS amounted to DKK 339 million.

Share options & restricted stock units

The group parent company Pfizer Inc. has established a share option and restricted stock unit scheme for employees within the Pfizer Group, including employees in Pfizer ApS. The options can be exercised from 2010 within a period from three to ten years after they are granted to the employee.

Financial obligations

The company is jointly taxed /VAT registered with other Danish companies in the Pfizer group. As a wholly owned subsidiary of Pfizer Inc., the company is unlimited and solidarity liable with the other companies in the joint taxation regarding Danish income tax, withholding taxes on dividends, interest and royalties in the joint taxation. Payable withholding taxes in the joint taxation are as of 30th November 2017 DKK 0. Any subsequent corrections of the taxable income in the joint taxation or withholding taxes could lead to the company's liability being higher.

18 Related party Disclosures

Pfizer ApS' related parties comprise the following:

Control

Pfizer ApS is owned 100% by Wyeth AB, Vetenskapsvägen 10, 191 90 Sollentuna, Sverige.

Furthermore, the Company is included in the consolidated financial statements of the ultimate parent company Pfizer Inc., 219-8-6A East 42nd Street, New York, N.Y. 10017, USA.

The consolidated financial statements of Pfizer Inc are available at the Company's address or on the Company's website at www.pfizer.com.

Related party transactions

The Company has chosen only to disclose transactions that are not carried out on an arm's length basis in accordance with section 98c(7) of the Danish Financial Statements Act. There are no such transactions.